Cresco Labs Inc.
CL.CNCNQHealthcare● Active
$1.33
+$0.09(+7.26%)
Market Cap$471120025
P/E Ratio—
52W High$3.12
52W Low$0.6
Cresco Labs Inc. (CL.CN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CL.CN · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 8, 2026EPS Actual
-$0.06
Est. -$0.03 · -95.3%
Revenue
$0.21B
Est. $0.21B · +1.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 8, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
CL.CN reports quarterly as a CNQ-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.02 | — | — | — | $0.23B | — |
| ▼ Q2 FY2026 | May 8, 2026 | -$0.03 | -$0.06 | -95.3% | $0.21B | $0.21B | +1.9% |
| ▼ Q1 FY2026 | Mar 11, 2026 | -$0.02 | -$0.33 | -1503.0% | $0.22B | $0.22B | +0.5% |
| ▼ Q4 FY2025 | Nov 5, 2025 | -$0.03 | -$0.07 | -137.7% | $0.23B | $0.16B | +43.0% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.03 | -$0.06 | -116.6% | $0.22B | $0.17B | +31.7% |
| — Q2 FY2025 | May 30, 2025 | -$0.04 | -$0.04 | +0.0% | $0.24B | $0.17B | +42.6% |
| ▲ Q1 FY2025 | Mar 11, 2025 | -$0.02 | -$0.02 | +9.8% | $0.25B | $0.17B | +51.0% |
| ▼ Q4 FY2024 | Nov 8, 2024 | -$0.01 | -$0.03 | -500.0% | $0.24B | $0.17B | +41.8% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.02
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 8, 2026Miss
EPS Actual
-$0.06
EPS Est.
-$0.03
EPS Surpr.
-95.3%
Revenue
$0.21B
Q1 FY2026
Mar 11, 2026Miss
EPS Actual
-$0.33
EPS Est.
-$0.02
EPS Surpr.
-1503.0%
Revenue
$0.22B
Q4 FY2025
Nov 5, 2025Miss
EPS Actual
-$0.07
EPS Est.
-$0.03
EPS Surpr.
-137.7%
Revenue
$0.23B
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.06
EPS Est.
-$0.03
EPS Surpr.
-116.6%
Revenue
$0.22B
Q2 FY2025
May 30, 2025
EPS Actual
-$0.04
EPS Est.
-$0.04
EPS Surpr.
+0.0%
Revenue
$0.24B
Q1 FY2025
Mar 11, 2025Beat
EPS Actual
-$0.02
EPS Est.
-$0.02
EPS Surpr.
+9.8%
Revenue
$0.25B
Q4 FY2024
Nov 8, 2024Miss
EPS Actual
-$0.03
EPS Est.
-$0.01
EPS Surpr.
-500.0%
Revenue
$0.24B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2027 | $0.01 | $0.01 | $0.01 | 1 |
| Q3 FY2027 | $0.00 | $0.00 | $0.00 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.2B | $0.2B | $0.2B | 4 |
| Q3 FY2028 | $0.2B | $0.2B | $0.2B | 4 |
| Q2 FY2028 | $0.2B | $0.2B | $0.2B | 5 |
| Q1 FY2028 | $0.2B | $0.2B | $0.2B | 2 |
| Q4 FY2027 | $0.2B | $0.2B | $0.2B | 3 |
| Q3 FY2027 | $0.2B | $0.2B | $0.2B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 8, 2026 | -95.3% | $1.50 | $1.42 | -5.33% |
| ▼ Q1 FY2026 | Mar 11, 2026 | -1503.0% | $1.27 | $1.35 | +6.30% |
| ▼ Q4 FY2025 | Nov 5, 2025 | -137.7% | $1.50 | $1.56 | +4.00% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -116.6% | $0.92 | $0.92 | +0.00% |
| ▲ Q2 FY2025 | May 30, 2025 | +0.0% | $0.92 | $0.84 | -8.70% |
| ▲ Q1 FY2025 | Mar 11, 2025 | +9.8% | $1.05 | $1.06 | +0.95% |
| ▼ Q4 FY2024 | Nov 8, 2024 | -500.0% | $1.76 | $1.75 | -0.57% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -2054.2% | $1.97 | $2.22 | +12.69% |
Q2 FY2026-5.33%
Report Date
May 8, 2026
EPS Beat/Miss
-95.3%
Price Before
$1.50
Price After
$1.42
Q1 FY2026+6.30%
Report Date
Mar 11, 2026
EPS Beat/Miss
-1503.0%
Price Before
$1.27
Price After
$1.35
Q4 FY2025+4.00%
Report Date
Nov 5, 2025
EPS Beat/Miss
-137.7%
Price Before
$1.50
Price After
$1.56
Q3 FY2025+0.00%
Report Date
Aug 7, 2025
EPS Beat/Miss
-116.6%
Price Before
$0.92
Price After
$0.92
Q2 FY2025-8.70%
Report Date
May 30, 2025
EPS Beat/Miss
+0.0%
Price Before
$0.92
Price After
$0.84
Q1 FY2025+0.95%
Report Date
Mar 11, 2025
EPS Beat/Miss
+9.8%
Price Before
$1.05
Price After
$1.06
Q4 FY2024-0.57%
Report Date
Nov 8, 2024
EPS Beat/Miss
-500.0%
Price Before
$1.76
Price After
$1.75
Q3 FY2024+12.69%
Report Date
Aug 8, 2024
EPS Beat/Miss
-2054.2%
Price Before
$1.97
Price After
$2.22
Avg Beat Reaction-3.87%
Avg Miss Reaction+2.85%
Beat Rate2 / 8 quarters
Largest Move+12.69% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CL.CN ends December
Cresco Labs Inc. (CL.CN) most recently reported earnings on May 8, 2026 for Q2 FY2026, posting EPS of $-0.06 — missing the analyst consensus of $-0.03 by -95.3%. The next CL.CN earnings date is expected around September 1, 2026.
Each quarter, investors track CL.CN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CL.CN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CL.CN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CL.CN earnings · 5 questionsCresco Labs Inc.'s next earnings report is expected around September 1, 2026. CL.CN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CL.CN historically reports after market close (AMC).
CL.CN earnings datewhen is CL.CN earningsCL.CN next earnings datewhen does CL.CN report earningsCL.CN earnings calendar
▸ Source: FMP · Cresco Labs Inc. SEC filings · US GAAP · Cresco Labs Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026